申请人:Zeneca Limited
公开号:US05332757A1
公开(公告)日:1994-07-26
The invention concerns oxime derivatives of the formula I ##STR1## wherein R.sup.4 includes hydrogen, carboxy, carbamoyl, amino, cyano, trifluoromethyl, (1-4C)alkylamino, di-(1-4C)alkylamino and (1-4C)alkyl; R.sup.5 includes hydrogen, (1-4C)alkyl, (3-4C)alkenyl, (3-4C)alkynyl, (2-5C)alkanoyl, halogeno-(2-4C)alkyl and hydroxy-(2-4C)alkyl; Ar.sup.1 is phenylene or a heteroaryl diradical; A.sup.1 is a direct link to X.sup.1, or A.sup.1 is (1-4C)alkylene; X.sup.1 is oxy, thio, sulphinyl or sulphonyl; Ar.sup.2 is phenylene or a heteroaryl diradical; R.sup.1 is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; and R.sup.2 and R.sup.3 together form a group of the formula -A.sup.2 -X.sup.2 -A.sup.3 - which together with the carbon atom to which A.sup.2 and A.sup.3 are attached define a ring having 5 or 6 ring atoms, wherein each of A.sup.2 and A.sup.3 is (1-3C)alkylene and X.sup.2 is oxy, thio, sulphinyl, sulphonyl or imino; or a pharmaceutically-acceptable salt thereof; processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.
该发明涉及公式I的肟衍生物
其中R.sup.4包括氢、羧基、氨基甲酰基、氨基、氰基、三氟甲基、(1-4C)烷基氨基、二-(1-4C)烷基氨基和(1-4C)烷基;R.sup.5包括氢、(1-4C)烷基、(3-4C)烯基、(3-4C)炔基、(2-5C)烷酰基、卤代-(2-4C)烷基和羟基-(2-4C)烷基;Ar.sup.1是苯基或杂环双基;A.sup.1是直接连接到X.sup.1的连接,或者A.sup.1是(1-4C)烷基;X.sup.1是氧、硫、亚砜基或砜基;Ar.sup.2是苯基或杂环双基;R.sup.1是(1-4C)烷基、(3-4C)烯基或(3-4C)炔基;R.sup.2和R.sup.3一起形成一个具有5或6个环原子的环的基团,其中A.sup.2和A.sup.3中的每一个是(1-3C)烷基,X.sup.2是氧、硫、亚砜基、砜基或亚胺;或其药学上可接受的盐;其制备方法;含有它们的药物组合物以及它们作为5-脂氧合酶抑制剂的用途。